Advertisement

Potential harms outweigh benefits of indefinite monitoring of stable adnexal masses

Published:September 09, 2015DOI:https://doi.org/10.1016/j.ajog.2015.09.005
      The management of women with asymptomatic adnexal masses should aim to balance potential benefit with potential harm. While masses with highly worrisome features or other signs of malignancy should be referred for surgery, the vast majority of masses have an indeterminate or benign appearance and are candidates for observation. Evidence supports the use of initial short-term serial ultrasound in distinguishing between benign and malignant masses. However, benefit from prolonged, potentially life-long monitoring of stable masses has not been demonstrated. Since the goal of monitoring an adnexal mass is to observe for worrisome growth or increasing complexity as an indicator of malignancy, if the mass remains stable, the likelihood of malignancy and therefore, the potential benefit of observation wanes with time. The recognition that Type 2 high grade serous cancers, which are responsible for the majority of deaths from ovarian cancer, arise from fallopian tube rather than ovarian precursors, further diminishes the likelihood that monitoring a stable ovarian mass will lead to early diagnosis of high grade disease. While some Type 1 cancers may develop from ovarian precursors, the available data suggest that any measurable benefit of monitoring known lesions for detection of these cancers is realized within the first year of observation. The argument in favor of indefinite, potentially life-long monitoring of stable masses also fails to adequately account for the risks of perpetual imaging, which include the risk of incidental findings, an increased likelihood of unnecessary surgery, patient anxiety and cost. It is not always better to order a test than not order a test. Given the absence of evidence of benefit, observation of stable small adnexal masses should be limited in duration in order to minimize potential harms.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Suh-Burgmann E.
        • Hung Y.Y.
        • Kinney W.
        Outcomes from ultrasound follow-up of small complex adnexal masses in women over 50.
        Am J Obstet Gynecol. 2014; 211: 623.e1-623.e7
        • American College of Obstetrics and Gynecology
        Management of adnexal masses. ACOG Practice bulletin no. 83.
        Obstet Gynecol. 2007; 110: 201-214
      1. Muto M. Management of an adnexal mass. In: Post TW, ed. UpToDate. Waltham, MA (Accessed Feb. 2, 2015).

        • Ormsby E.L.
        • Pavlik E.J.
        • Van Nagell J.R.
        Ultrasound follow up of an adnexal mass has the potential to save lives.
        Am J Obstet Gynecol. 2015; 213: 657-661
        • Sharma A.
        • Apostolidou S.
        • Burnell M.
        • et al.
        Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
        Ultrasound Obstet Gynecol. 2012; 40: 338-344
        • Daly M.G.
        • Dresher C.W.
        • Yates M.S.
        • et al.
        Salpingectomy as a means to reduce ovarian cancer risk.
        Cancer Prev Res (Phila). 2015; 8: 342-348
        • Kurman R.J.
        Origin and molecular pathogenesis of ovarian high grade serous carcinoma.
        Ann Oncol. 2013; 24: x16-x21
        • Lim D.
        • Oliva E.
        Precursors and pathogenesis of ovarian carcinoma.
        Pathology. 2013; 45: 229-242
        • Levine D.
        • Brown D.L.
        • Andreotti R.F.
        • et al.
        Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement.
        Radiology. 2010; 256: 943-954
        • World Health Organization Classification of Tumors Working Group on Gynecologic Tumors
        Tumors of the ovary and peritoneum.
        in: Tavassoli F.A. Devilee P. Pathology and genetics: tumors of the breast and female genital organs. IARC Press, Lyon (France)2003: 124-127
        • Kosary C.L.
        Cancer of the ovary.
        in: Ries L.A.G. Young J.L. Keel G.E. Eisner M.P. Lin Y.D. Horner M.J. SEER survival monograph: cancer survival among adults -U.S. SEER program, 1988-2001, patient and tumor characteristics. Publication no. 07-6215. National Cancer Institute, Bethesda, Md2007: 133-144
        • Baldwin L.M.
        • Trivers K.F.
        • Matthews B.
        • et al.
        Vignette-based study of ovarian cancer screening: do US physicians report adhering to evidence-based recommendations?.
        Ann Intern Med. 2012; 156: 182-194
        • Reade C.J.
        • Riva J.J.
        • Busse J.W.
        • Goldsmith C.H.
        • Elit L.
        Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis.
        Gynecol Oncol. 2013; 130: 674-681
      2. Gawande A. Overkill: America’s epidemic of unnecessary care. New Yorker. May 11, 2015. Available at: http://www.newyorker.com/magazine/2015/05/11/overkill-atul-gawande. Accessed November 9, 2015.

        • Valentin L.
        • Skoog L.
        • Epistein E.
        Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation.
        Ultrasound Obstet Gynecol. 2003; 22: 284-289
        • Buys S.S.
        • Partridge E.
        • Black A.
        • et al.
        • PLCO Project Team
        Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
        JAMA. 2011; 305: 2295-2303